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How commensal-specific T cells are controlled in the periphery is poorly understood. In a recent issue of
Science, Hepworth et al. (2015) show that ILC3s induce apoptosis of microbiota-specific CD4 T cells in a
form of extrathymic negative selection.Discriminating between self and non-self
is one of the most important and chal-
lenging functions of the immune system.
This includes the ability to generate re-
sponses against non-self, i.e., immunity,
while avoiding overt responses to self,
i.e., autoimmunity. During T cell develop-
ment in the thymus, potentially dangerous
T cell clones recognizing host self-anti-
gens are either eliminated or re-directed
to alternative fates, such as the T regula-
tory (Treg) cell lineage. The deletion of au-
toreactive T cells, or negative selection, is
directed by ectopic expression of tissue-
restricted self-antigens presented by
MHCII on medullary thymic epithelial cells
(mTEC).
The mammalian gut contains trillions
of resident commensal bacteria that
are physically and functionally integrated
with the host. In order to avoid self-reac-
tivity in the host-microbe superorganism,
the immune system must ensure unre-
sponsiveness to the commensal ‘‘self.’’
The mechanisms that constrain activation
of commensal-specific T cells are poorly
understood. As bacterial antigens are
not encoded in the host genome,
commensal-specific CD4 T cells escape
deletion in the thymus. Nevertheless,
commensal-specific effector CD4 T cells
are not expanded or engaged in the intes-
tine at steady state. This ismainly achieved
by limiting the exposure of the immune
system to most commensal bacteria and
their antigens (Hooper and Macpherson,
2010). However, even though they do
not normally gain access across the
epithelial barrier, commensal bacteria
and their products are sampled by the
host. This seems to be a well-regulated
process mediated by transport of small
amounts of antigens to mesenteric lymph
nodes (MLNs) by lamina propria (LP) den-
dritic cells (DCs) (Hapfelmeier et al., 2010;
Macpherson and Uhr, 2004). At steady12 Immunity 43, July 21, 2015 ª2015 Elseviestate, this directed sampling by mostly
tolerogenic LP DCs restricts commensal
CD4 T cell reactivities by diverting them
into the Treg cell lineage (Grainger et al.,
2014).
In a recent study in Science, the Son-
nenberg group reports another mecha-
nism of preventing commensal-specific
CD4 T cell expansion (Hepworth et al.,
2015). They find that MHCII-expressing
group 3 innate lymphoid cells (ILC3s) can
curtail commensal-specific CD4 T cells in
a process akin to negative selection in
the thymus, termed ‘‘intestinal selection.’’
ILC3s regulate MHCII expression similarly
to mTECs and are capable of inducing
apoptosis of CD4 T cells in an MHCII-
and antigen-dependent manner.
Previous work demonstrated a role
for ILC3s in controlling CD4 T cell re-
sponses in the gut via expression of
MHCII (Goto et al., 2014; Hepworth
et al., 2013). Conditional ablation ofMHCII
expression on ILC3s (in MHCIIDILC3 mice)
leads to uncontrolled intestinal inflamma-
tion with significant expansion of acti-
vated CD4 T cells that produce pro-in-
flammatory cytokines (Hepworth et al.,
2013). MHCIIDILC3 mice in a different col-
ony show expansion of T helper 17
(Th17) cells in the small intestine in the
absence of inflammation, suggesting
that the defect in CD4 T cell homeostasis
is the initiating factor and that specific mi-
crobiota might drive inflammation (Goto
et al., 2014). Indeed, antibiotic treatment
abolishes both CD4 T cell activation and
intestinal inflammation in this model,
proving that inflammation is microbiota-
driven and suggesting that the expanded
CD4 T cells recognize commensal anti-
gens (Hepworth et al., 2013). How exactly
MHCII+ ILC3s control mucosal CD4
T cells remained unclear.
In order to address this question, Hep-
worth et al. characterized the regulationr Inc.of MHCII expression on ILC3s. This
expression is restricted to a subset of
ILC3s known as lymphoid-tissue inducer
(Lti) cells that express the chemokine re-
ceptor CCR6 and are enriched in the
MLN and intestinal LP. In contrast to
non-professional antigen-presenting cells
(APCs) such as epithelial cells, MHCII
expression on ILC3s is constant and inde-
pendent of cytokine signals, presence of
microbiota, and microbial-derived stimuli.
In contrast to peripheral APCs such as
B cells and DCs, MHCII expression on
ILC3s is under the control of the pIV pro-
moter of the master MHCII transcriptional
regulator CIITA. The only other APCs with
similar MHCII regulation are mTECs,
which direct negative selection in the
thymus. This led the authors to explore
the possibility that ILC3s mediate extra-
thymic negative selection of commensal
CD4 T cells. Indeed, ILC3-specific dele-
tion of MHCII in MHCIIDILC3 mice leads
to loss of tolerance to the microbiota
and expansion of activated CD4 T cells
that recognize commensal bacteria in
the LP.
Do ILC3s restrain all types of CD4
T cells? To address this question, Hep-
worth et al. examined the effects of
ILC3s on TCR transgenic (Tg) T cells spe-
cific for either food antigens (chicken
ovalbumin, OTII) or commensal bacteria
(commensal flagelin, CBir1). Using a com-
bination of genetic approaches, the au-
thors demonstrate that ILC3s restrict
expansion of CD4 T cells only in the pres-
ence of cognate antigen. As ILC3s in the
MLN present mostly commensal anti-
gens, they preferentially control CD4
T cells recognizing such antigens. Indeed,
in the absence of exogenous antigen,
expansion of CD4 T cells and intestinal
inflammation occur only in MHCIIDILC3
mice crossed to CBir1-Tg, but not to
OTII-Tg mice, and only in intestinal
Figure 1. Selection of Self-Reactive and Commensal-Specific CD4 T Cells
(Left) In the thymus, bone marrow-derived APCs, such as DCs, and mTECs eliminate self-reactive CD4 T cells either through the induction of apoptosis during
negative selection or re-direction to the Treg cell lineage.
(Right) In theMLN, activated commensal-specific CD4 T cells are either directed to the Treg cell lineage by CD103+ DCs or deleted through induction of apoptosis
by MHCII+ ILC3s in a process of ‘‘intestinal selection.’’ ILC3s induce apoptosis by IL-2 withdrawal, which activates Nur77 and the proapoptotic factor Bim. Con-
ditional deletion of MHCII on ILC3 (MHCIIDILC3 mice) prevents deletion and leads to expansion of commensal-specific CD4 T cells, which results in intestinal
inflammation in the presence of appropriate microbiota.
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Previewstissues. In contrast, preferential CD4
T cell expansion is not detected in the
thymus or spleen. Moreover, transfer of
activated CD4 T cells together with
cognate antigen into congenic animals in
which only ILC3s express MHCII results
in decreased recovery of CBir1 Tg
T cells in the MLN and LP compared to
MHCII-negative hosts. Interestingly, the
decreased recovery is not a result of
decreased trafficking or proliferation of
transferred T cells, nor does it seem to
re-direct cells to the Treg cell fate. This
led the authors to examine whether
ILC3s induce MHCII-mediated apoptosis
of commensal T cells. To better study
this question, they developed an in vitro
co-culture system, where they first show
that intestinal ILC3s can restrict expan-
sion of activated CD4 T cells in an
MHCII-dependent and antigen-depen-
dent manner, underscoring the specificity
of this effect and recapitulating the in vivo
phenomenon. ILC3s induce apoptosis of
target CD4 T cells in vitro in an antigen-
dependent manner. Similarly to mTEC-
mediated central negative selection,
ILC3-induced apoptosis is accompanied
by induction of Nur77 and the proapopto-
tic factor Bim in CD4 T cells, and ILC3s
do not induce death in Bim-deficientCD4 T cells. Because Bim-dependent
apoptotic cell death can be induced by
cytokine starvation and ILC3s constitu-
tively express common gamma chain
cytokine receptors, the authors examined
whether addition of several key cytokines
can rescue apoptotic CD4 T cells.
Indeed, addition of recombinant inter-
leukin-2 (IL-2) rescues CD4 T cells from
ILC3-induced apoptosis and mutant
T cells with constitutively active IL-2
signaling can escape deletion by ILC3s
both in vitro and following adoptive trans-
fer in vivo.
Altogether, the data in this study estab-
lish a model in which presentation of
commensal antigens by ILC3s leads to
apoptosis of cognate CD4 T cells in the
MLN, mediated by sequestration of IL-2
by ILCs (Figure 1). This results in a signif-
icant decrease in commensal-specific
activated CD4 T cells in the gut mucosa,
which is crucial for preserving host-
commensal mutualism. Further expand-
ing the impact of their study, the authors
report that MHCII expression by ILC3s
is also present in human intestinal tissues
and is dysregulated during inflammatory
bowel disease (IBD). Crohn’s disease
patients have significantly decreased
expression of MHCII on mucosal ILC3s,Immunwhich inversely correlates with fre-
quencies of pro-inflammatory colonic
Th17 cells and the amount of circulating,
commensal bacteria-specific IgG. Thus,
ILC3-mediated ‘‘intestinal selection’’
may represent a genuine therapeutic
target in IBD.
Several questions remain to be ad-
dressed in future studies, central of which
is the contribution of this new pathway of
intestinal selection to steady state
commensal homeostasis in vivo. In the
LP, ILC3s are key participant in the cross-
talk between the microbiota and innate
and adaptive immune cells (Mortha
et al., 2014). It will be important to
examine whether the molecular mecha-
nisms of induced apoptosis outlined by
the elegant in vitro studies are the only
mechanisms mediating MHCII+ ILC3 ef-
fects in vivo. It is important that ILC3s do
not completely purge commensal-reac-
tive CD4 T cells from the repertoire,
because this would be detrimental.
Indeed, Hepworth et al. show that only
activated, and not naive, CD4 T cells
could be controlled by ILC3s. This en-
sures preservation of commensal-reac-
tive TCRs in the naive CD4 T cell pool
that can deal with commensal dissemina-
tion in the event of epithelial barrierity 43, July 21, 2015 ª2015 Elsevier Inc. 13
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this difference in specificity remain to be
elucidated. The nature, location, and
mode of acquisition of commensal anti-
gens by ILC3s will also be important to
ascertain. Very few commensal bacteria
gain access to the MLN (Hapfelmeier
et al., 2010) and at steady state most are
delivered by tolerogenic DCs that induce
Treg cells. MLN DCs from wild-type
mice fail to stimulate CBir1 T cells
in vitro, suggesting that they lack endoge-
nous CBir1 antigens at steady state (Cong
et al., 2009). This agrees with the results in
the current study where adoptively trans-
ferred CBir1 T cells require administration
of exogenous antigen for control by
ILC3s. How do ILC3s then acquire
commensal antigens and what are these
antigens? One possibility is that this
pathway is initiated under conditions of
increased commensal antigen burden.
Another possibility is that ILC3s sample
antigens and restrict T cell activation
against a subset of commensal bacteria.
ILC3s might also receive antigens from14 Immunity 43, July 21, 2015 ª2015 ElsevieDCs in either the MLN or LP. Although
ILC3s co-localize with T cells in the
MLN, they can also traffic from the LP to
the MLN (Mackley et al., 2015) and might
acquire antigens or exert intestinal selec-
tion in the mucosa itself.
Understanding how the immune system
preserves mutualism with commensal mi-
crobiota is central to our ability to sustain
healthy immune homeostasis. The study
by Hepworth et al. describes not only a
new function for ILCs, but also a new
mechanism for maintaining intestinal
homeostasis that introduces exciting
opportunities for unconventional thera-
peutic approaches to chronic inflamma-
tory disorders.REFERENCES
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